KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Accured Expenses (2020 - 2025)

Recursion Pharmaceuticals' Change in Accured Expenses history spans 6 years, with the latest figure at $15.8 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 50.56% year-over-year to $15.8 million; the TTM value through Dec 2025 reached -$7.4 million, down 234.21%, while the annual FY2025 figure was -$7.4 million, 234.21% down from the prior year.
  • Change in Accured Expenses reached $15.8 million in Q4 2025 per RXRX's latest filing, up from -$8.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $15.8 million in Q4 2025 to a low of -$26.6 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $850950.0, with a median of $2.4 million recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: soared 1156.33% in 2021, then crashed 11680.0% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.6 million in 2021, then soared by 641.26% to $12.2 million in 2022, then plummeted by 77.12% to $2.8 million in 2023, then skyrocketed by 278.01% to $10.5 million in 2024, then soared by 50.56% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Change in Accured Expenses are $15.8 million (Q4 2025), -$8.0 million (Q3 2025), and $11.4 million (Q2 2025).